VELAKAST is a fixed-dose combination of two direct-acting antivirals. Sofosbuvir inhibits the NS5B RNA polymerase, while Velpatasvir targets the NS5A protein—both crucial to the replication of the hepatitis C virus.
Recommended for:
Adults diagnosed with chronic HCV infection
All genotypes (1 to 6)
As monotherapy or in combination
With or without compensated cirrhosis
Chronic hepatitis C virus (HCV) infection in adults of any genotype
Take orally once daily with or without food, for 12 weeks. Treatment duration and combination with other agents should be prescribed by a healthcare professional.
Contraindications:
Hypersensitivity to sofosbuvir, velpatasvir, or excipients
Severe hepatic impairment without monitoring
Under 18 years of age
Concurrent use with medications that significantly reduce active drug levels (e.g., rifampin)
Side Effects:
Headache
Fatigue
Nausea
Diarrhoea
Sleep disturbances
Elevated liver enzymes
